Cory Renauer
Value, research analyst, biotech, small-cap

Dark Days Ahead For Amicus, Reasons You Shouldn't Fold

The Amicus Therapeutics (NASDAQ:FOLD) pipeline consists of novel, first-in-class treatments for a range of genetic diseases. The most advanced compounds along its pipeline address the largely unmet needs of patients with lysosomal storage disorders ((LSDs)).

Lysosomes, if you are having trouble remembering, are the cell's waste disposal system. They engulf and break down worn out organelles, bacteria, viruses, and play a large role in food digestion. LSD causes vary, but most often deficiency in a specific enzyme function leads to a buildup of debris, almost like a city with garbage collectors on strike.

Amicus uses pharmacological chaperone technology to develop small molecules, or chaperones that selectively binds to LSD specific target proteins, keeping them folded in the correct,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details